Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors
The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer. Retrospective review of consecutive cases treated at our Breast Unit between 2003 and...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2024-05, Vol.29 (5), p.384-391 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 391 |
|---|---|
| container_issue | 5 |
| container_start_page | 384 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 29 |
| creator | Dajti, Gerti Serra, Margherita Cisternino, Giovanni Ceccarelli, Claudio Pellegrini, Alice Melina, Marica De Leo, Antonio Santini, Donatella Taffurelli, Mario Zanotti, Simone |
| description | The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer.
Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression.
A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer.
p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer. |
| doi_str_mv | 10.1093/oncolo/oyad309 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2893841051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A795056543</galeid><sourcerecordid>A795056543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-e086c0c1fd038af5b9bbfa21398257e360a4934fe2fc04c6008dee4e008033223</originalsourceid><addsrcrecordid>eNptkU2P0zAQhiMEYj_gyhFZ4sIlrZ2Jm_hYKna3UgWr7iK4Ra4zbg2J3bWdrvbX8Fdx1II4rOYwo5lnXo3mzbJ3jE4YFTB1VrnOTd2TbIGKF9k546XIS0F_vEw1rSGvGBdn2UUIPylNJRSvszOohODA2Hn2-9a7rXUhGkXWrkPiNNlzIMu-H6zbmRCd2mFvlOzIXZRxCMRYsrQHGcwBySePMkSykFahn5A5WWP0LuxRxXG8xoPBx1GTQV0lLGAg303ckdXQGyu7fGV-4fQGfUG-4FbG_zTvh9758CZ7pWUX8O0pX2bfrj7fL27y1dfr5WK-yhXwKuZI65miiumWQi0134jNRsuCgagLXiHMqCwFlBoLrWipZpTWLWKJKVOAooDL7ONRd-_dw4AhNr0JCrtOWnRDaIpaQF0yyllCPxzRreywMVa76KUa8WZeCU75jJeQqMkzVIp2_KazqE3qP7eg0gODR93svemlf2oYbUavm6PXzcnrtPD-dPKw6bH9h_81F_4AjOWm2g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2893841051</pqid></control><display><type>article</type><title>Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Dajti, Gerti ; Serra, Margherita ; Cisternino, Giovanni ; Ceccarelli, Claudio ; Pellegrini, Alice ; Melina, Marica ; De Leo, Antonio ; Santini, Donatella ; Taffurelli, Mario ; Zanotti, Simone</creator><creatorcontrib>Dajti, Gerti ; Serra, Margherita ; Cisternino, Giovanni ; Ceccarelli, Claudio ; Pellegrini, Alice ; Melina, Marica ; De Leo, Antonio ; Santini, Donatella ; Taffurelli, Mario ; Zanotti, Simone</creatorcontrib><description>The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer.
Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression.
A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer.
p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1093/oncolo/oyad309</identifier><identifier>PMID: 37995311</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - metabolism ; Breast cancer ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Development and progression ; Disease-Free Survival ; Female ; Health aspects ; Humans ; Immunohistochemistry - methods ; Middle Aged ; Neoplasm Invasiveness ; Patient outcomes ; Physiological aspects ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Retrospective Studies ; Tumor proteins ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>The oncologist (Dayton, Ohio), 2024-05, Vol.29 (5), p.384-391</ispartof><rights>The Author(s) 2023. Published by Oxford University Press.</rights><rights>COPYRIGHT 2024 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-e086c0c1fd038af5b9bbfa21398257e360a4934fe2fc04c6008dee4e008033223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37995311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dajti, Gerti</creatorcontrib><creatorcontrib>Serra, Margherita</creatorcontrib><creatorcontrib>Cisternino, Giovanni</creatorcontrib><creatorcontrib>Ceccarelli, Claudio</creatorcontrib><creatorcontrib>Pellegrini, Alice</creatorcontrib><creatorcontrib>Melina, Marica</creatorcontrib><creatorcontrib>De Leo, Antonio</creatorcontrib><creatorcontrib>Santini, Donatella</creatorcontrib><creatorcontrib>Taffurelli, Mario</creatorcontrib><creatorcontrib>Zanotti, Simone</creatorcontrib><title>Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer.
Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression.
A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer.
p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Development and progression</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Patient outcomes</subject><subject>Physiological aspects</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Retrospective Studies</subject><subject>Tumor proteins</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU2P0zAQhiMEYj_gyhFZ4sIlrZ2Jm_hYKna3UgWr7iK4Ra4zbg2J3bWdrvbX8Fdx1II4rOYwo5lnXo3mzbJ3jE4YFTB1VrnOTd2TbIGKF9k546XIS0F_vEw1rSGvGBdn2UUIPylNJRSvszOohODA2Hn2-9a7rXUhGkXWrkPiNNlzIMu-H6zbmRCd2mFvlOzIXZRxCMRYsrQHGcwBySePMkSykFahn5A5WWP0LuxRxXG8xoPBx1GTQV0lLGAg303ckdXQGyu7fGV-4fQGfUG-4FbG_zTvh9758CZ7pWUX8O0pX2bfrj7fL27y1dfr5WK-yhXwKuZI65miiumWQi0134jNRsuCgagLXiHMqCwFlBoLrWipZpTWLWKJKVOAooDL7ONRd-_dw4AhNr0JCrtOWnRDaIpaQF0yyllCPxzRreywMVa76KUa8WZeCU75jJeQqMkzVIp2_KazqE3qP7eg0gODR93svemlf2oYbUavm6PXzcnrtPD-dPKw6bH9h_81F_4AjOWm2g</recordid><startdate>20240503</startdate><enddate>20240503</enddate><creator>Dajti, Gerti</creator><creator>Serra, Margherita</creator><creator>Cisternino, Giovanni</creator><creator>Ceccarelli, Claudio</creator><creator>Pellegrini, Alice</creator><creator>Melina, Marica</creator><creator>De Leo, Antonio</creator><creator>Santini, Donatella</creator><creator>Taffurelli, Mario</creator><creator>Zanotti, Simone</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240503</creationdate><title>Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors</title><author>Dajti, Gerti ; Serra, Margherita ; Cisternino, Giovanni ; Ceccarelli, Claudio ; Pellegrini, Alice ; Melina, Marica ; De Leo, Antonio ; Santini, Donatella ; Taffurelli, Mario ; Zanotti, Simone</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-e086c0c1fd038af5b9bbfa21398257e360a4934fe2fc04c6008dee4e008033223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Development and progression</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Patient outcomes</topic><topic>Physiological aspects</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Retrospective Studies</topic><topic>Tumor proteins</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dajti, Gerti</creatorcontrib><creatorcontrib>Serra, Margherita</creatorcontrib><creatorcontrib>Cisternino, Giovanni</creatorcontrib><creatorcontrib>Ceccarelli, Claudio</creatorcontrib><creatorcontrib>Pellegrini, Alice</creatorcontrib><creatorcontrib>Melina, Marica</creatorcontrib><creatorcontrib>De Leo, Antonio</creatorcontrib><creatorcontrib>Santini, Donatella</creatorcontrib><creatorcontrib>Taffurelli, Mario</creatorcontrib><creatorcontrib>Zanotti, Simone</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dajti, Gerti</au><au>Serra, Margherita</au><au>Cisternino, Giovanni</au><au>Ceccarelli, Claudio</au><au>Pellegrini, Alice</au><au>Melina, Marica</au><au>De Leo, Antonio</au><au>Santini, Donatella</au><au>Taffurelli, Mario</au><au>Zanotti, Simone</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2024-05-03</date><risdate>2024</risdate><volume>29</volume><issue>5</issue><spage>384</spage><epage>391</epage><pages>384-391</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer.
Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression.
A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer.
p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>37995311</pmid><doi>10.1093/oncolo/oyad309</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2024-05, Vol.29 (5), p.384-391 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2893841051 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Development and progression Disease-Free Survival Female Health aspects Humans Immunohistochemistry - methods Middle Aged Neoplasm Invasiveness Patient outcomes Physiological aspects Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Retrospective Studies Tumor proteins Tumor Suppressor Protein p53 - metabolism |
| title | Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T20%3A25%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Role%20of%20p53%20Immunohistochemical%20Status%20in%20Invasive%20Breast%20Cancer.%20A%20Retrospective%20Review%20of%201387%20Cases%20With%20Luminal-Like/Her2%20Negative%20Breast%20Tumors&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Dajti,%20Gerti&rft.date=2024-05-03&rft.volume=29&rft.issue=5&rft.spage=384&rft.epage=391&rft.pages=384-391&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1093/oncolo/oyad309&rft_dat=%3Cgale_proqu%3EA795056543%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2893841051&rft_id=info:pmid/37995311&rft_galeid=A795056543&rfr_iscdi=true |